Mariana Socal: Today in STAT I shared some thoughts on the potential impact of the new drug price negotiation program on Medicare beneficiaries.
Mariana Socal, Assistant scientist in the Department of Health Policy and Management at Johns Hopkins Bloomberg School of Public Health, made the following post on Twitter:
“Today in STAT I shared some thoughts on the potential impact of the new drug price negotiation program on Medicare beneficiaries.
Pros: Lower out-of-pocket payments for beneficiaries & guaranteed coverage of the negotiated drugs by all Medicare Part D plans
Cons: plans can’t shift so much of the drug cost to beneficiaries & manufacturers can’t keep their prices confidential.
2 potential detrimental consequences to beneficiaries should be monitored: plans may increase barriers to access the negotiated drugs (prior authorization, step therapy) or may require higher copays than what the beneficiary would be paying under coinsurance with the new prices.”
For details click here
Source: Mariana Socal / Twitter
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023